US 12,215,160 B2
Treatment of patients having c-met exon 14 skipping mutations
Roland Knoblauch, Doylestown, PA (US); Sylvie Laquerre, Chesterbrook, PA (US); and Sheri Moores, Wayne, PA (US)
Assigned to Janssen Biotech, Inc., Horsham, PA (US)
Filed by Janssen Biotech, Inc., Horsham, PA (US)
Filed on Feb. 12, 2021, as Appl. No. 17/174,386.
Claims priority of provisional application 62/975,406, filed on Feb. 12, 2020.
Prior Publication US 2021/0253717 A1, Aug. 19, 2021
Int. Cl. A61P 35/00 (2006.01); A61K 31/53 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2863 (2013.01) [A61K 31/53 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/31 (2013.01)] 47 Claims
 
1. A method of treating a subject having a cancer that is positive for a c-Met exon 14 skipping mutation, the method comprising administering to the subject a combination therapy comprising:
a therapeutically effective amount of an isolated bispecific anti-epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody; and
a therapeutically effective amount of a compound of formula (I)

OG Complex Work Unit Chemistry
 or a pharmaceutically acceptable solvate, hydrate, tautomer, or salt thereof, wherein the bispecific anti-EGFR/c-Met antibody comprises:
a first domain that binds EGFR, the first domain comprising a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence of SEQ ID NO: 1, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 2, a HCDR3 comprising the amino acid sequence of SEQ ID NO: 3, a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence of SEQ ID NO: 4, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 6; and
a second domain that binds c-Met, the second domain comprising a HCDR1 comprising the amino acid sequence of SEQ ID NO: 7, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 8, a HCDR3 comprising the amino acid sequence of SEQ ID NO: 9, a LCDR1 comprising the amino acid sequence of SEQ ID NO: 10, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 11, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 12.